1. Home
  2. ANAB vs EVLV Comparison

ANAB vs EVLV Comparison

Compare ANAB & EVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$62.02

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Evolv Technologies Holdings Inc.

EVLV

Evolv Technologies Holdings Inc.

HOLD

Current Price

$6.07

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
EVLV
Founded
2005
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
ANAB
EVLV
Price
$62.02
$6.07
Analyst Decision
Buy
Strong Buy
Analyst Count
11
4
Target Price
$74.64
$9.13
AVG Volume (30 Days)
601.6K
3.5M
Earning Date
05-04-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
91.02
N/A
EPS
N/A
N/A
Revenue
$234,603,000.00
N/A
Revenue This Year
N/A
$21.67
Revenue Next Year
$31.11
$19.50
P/E Ratio
N/A
N/A
Revenue Growth
157.01
N/A
52 Week Low
$15.40
$3.10
52 Week High
$68.39
$8.90

Technical Indicators

Market Signals
Indicator
ANAB
EVLV
Relative Strength Index (RSI) 55.41 59.27
Support Level $43.67 $5.43
Resistance Level $67.69 $6.45
Average True Range (ATR) 4.07 0.28
MACD -0.57 0.06
Stochastic Oscillator 60.16 84.07

Price Performance

Historical Comparison
ANAB
EVLV

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About EVLV Evolv Technologies Holdings Inc.

Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.

Share on Social Networks: